Skip to content
DataLookout
Menu

ROXI-ASPENNCT07213778

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Nov 8, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 49 → 57 locations
  2. Minor Study sites: 49 to 51
  3. Minor Trial sites expanded: 46 → 49 locations
  4. Notable Eligibility criteria expanded, about 7 words
    • Trial sites expanded: 36 → 46 locations
  5. Minor Study sites: 34 to 36v14
  6. Minor Study sites: 32 to 34v13
  7. Minor Trial sites expanded: 28 → 32 locationsv12
  8. Minor Trial sites expanded: 23 → 28 locationsv11
  9. Minor Trial sites expanded: 19 → 23 locationsv10
  10. Notable Primary endpoint(s) modified
    • Trial sites expanded: 16 → 19 locations
    • Secondary endpoints revised (14)
    v9
  11. Minor Study sites: 14 to 16v8
  12. Minor Study sites: 13 to 14v7
  13. Minor Trial sites expanded: 10 → 13 locationsv6
  14. Minor Study sites: 9 to 10v5
  15. Minor Study sites: 5 to 9v4
  16. Minor Study sites: 2 to 5v3
  17. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Primary completion date: Jul 16, 2027 to May 17, 2027
    • Start date changed from estimate of Dec 5, 2025 to Nov 24, 2025
    v2
  18. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of the composite endpoint of symptomatic VTE and all-cause death
Timeframe: Through day 30 visit

Secondary (14)

Time to first event of the composite endpoint of symptomatic VTE and all-cause death
Incidence of confirmed symptomatic Deep Vein Thrombosis (DVT)
Incidence of confirmed Pulmonary Embolism (PE)
Incidence of all-cause death
Time to first event of the confirmed symptomatic DVT
Show 9 moreShow less
Time to first event of the confirmed PE
Time to the all-cause death
Incidence of the composite endpoint of major bleeding and Clinically Relevant Non-Major (CRNM) bleeding
Incidence of minor bleeding
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Incidence of Anti-drug Antibody (ADA) to REGN7508
Magnitude of ADA to REGN7508
Concentrations of REGN7508

Arms and interventions

REGN7508 and PlaceboExperimental
Placebo and ASAActive comparator

Drugs: REGN7508, Acetylsalicylic Acid (ASA), Placebo

Sites

57 sites in 5 countries

United States 42, Spain 6, Malaysia 5, Greece 3, Moldova 1